Zobrazeno 1 - 10
of 27
pro vyhledávání: '"J Thaddeus Beck"'
Autor:
Patrick Neven, Xavier Pivot, Antonia Ridolfi, Brad Lanoue, J. Thaddeus Beck, Guy Jerusalem, Arnd Nusch, Francisco J. Esteva, Giulia Bianchi, David Chandiwana, Miguel Martin, Karen Rodriguez Lorenc, Peter A. Fasching, Arlene Chan, Yingbo Wang, Michele De Laurentiis
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 54, Iss, Pp 148-154 (2020)
Breast, Vol 54, Iss, Pp 148-154 (2020)
Purpose In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and o
Autor:
Gabor Rubovszky, Aditya Bardia, J. Thaddeus Beck, Ross A. Stewart, Mateusz Opyrchal, Melinda L. Telli, Mustafa Khasraw, Smita S. Saraykar, David R. Wise, Mikhail Dvorkin, Anita Scheuber, Rossano Cesari, Panagiotis A. Konstantinopoulos, Anil A. Joy, Timothy A. Yap, Jame Abraham, Colombe Chappey, Matthew D. Galsky, Daria Stypinski
Publikováno v:
Cancer Research. 80:P1-19
Background: Avelumab, a human IgG1 anti–PD-L1 monoclonal antibody, has shown antitumor activity and a manageable safety profile in several tumor types. Talazoparib, an orally available PARP inhibitor, is approved for the treatment of patients with
Autor:
Antonio Cubillo Gracian, Marina Nechaeva, Ramesh K. Ramanathan, Danielle Sullivan, Jordan Berlin, Elena Elez Fernandez, Ralf Hofheinz, Vera Gorbunova, Dustin A. Deming, Alison Torres, J. Thaddeus Beck, Yan Luo, László Mangel, P. García-Alfonso
Publikováno v:
British Journal of Cancer
Background Metastatic colorectal cancer (mCRC) has low survival rates. We assessed if addition of veliparib, concurrent to FOLFIRI, improves survival in patients with previously untreated mCRC. Methods This study compared veliparib (200 mg BID for 7
Autor:
Maen A. Hussein, Raid Aljumaily, Shannon R. Morris, Bojan Zaric, Wahid Hanna, Didier Verhoeven, Z. Andric, Jie Xiao, J. Thaddeus Beck, Janakiraman Subramanian, Renata Ferrarotto, Joyce M Antal, Davorin Radosavljevic, Lowell L. Hart, Taofeek K. Owonikoko
Publikováno v:
Advances in therapy
Advances in Therapy
Advances in Therapy
Introduction Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications. Current therapies are lineage specific and administered after chemotherapy damage has occurred. Tril
Autor:
Seock-Ah Im, Francisco J. Esteva, Debu Tripathy, Denise A. Yardley, Joohyuk Sohn, Karen Rodriguez Lorenc, Juan Pablo Zarate, J. Thaddeus Beck, Howard A. Burris, Stephen Chia, Arlene Chan, Antonia Ridolfi, Patrick Neven, Lowell L. Hart, Aditya Bardia
Publikováno v:
Br J Cancer
Background This pooled analysis of MONALEESA trials evaluated the safety of ribociclib plus endocrine therapy (RIB + ET) with a focus on dose reductions in first-line patients. Methods In the dose reduction analysis, data were pooled from MONALEESA-2
Autor:
Xavier Pivot, Michelle Miller, Seock-Ah Im, Francisco J. Esteva, Yingbo Wang, Miguel Martin, Arnd Nusch, Luis de la Cruz-Merino, Karen Rodriguez Lorenc, Patrick Neven, Dennis J. Slamon, K. Petrakova, Peter A. Fasching, J. Thaddeus Beck, Stephen Chia, Michelino De Laurentiis, Gena Vidam, Guy Jerusalem, Giulia Val Bianchi, Gabe S. Sonke, Tetiana Taran
Publikováno v:
Journal of Clinical Oncology. 36:2465-2472
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer who were treatment naïve or had received up to one line of pri
Autor:
Robert S. Alter, J. Thaddeus Beck, Monika Joshi, Earle F. Burgess, David R. Shaffer, Mayer Fishman, Ralph J. Hauke, Nicholas J. Vogelzang, Martin H. Voss, Nauman Moazzam, Xiaosha Zhang, Chad E. Glasser, Elizabeth R. Plimack, Rupal S. Bhatt, Michael B. Atkins, Theodore F. Logan, Rahul A. Parikh, Matthew L. Sherman, Brian I. Rini
Publikováno v:
Cancer
BACKGROUND In a prior open-label study, the combination of dalantercept, a novel antiangiogenic targeting activin receptor-like kinase 1 (ALK1), plus axitinib was deemed safe and tolerable with a promising efficacy signal in patients with advanced re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0196483f823f2190dadaf46fe5ecb04c
https://europepmc.org/articles/PMC6602847/
https://europepmc.org/articles/PMC6602847/
Autor:
Karen Kelly, J. Thaddeus Beck, Manish R. Patel, Hans Juergen Grote, Jaspreet Grewal, Anja von Heydebreck, Michael S. Gordon, Vikram Chand, Christina M. Annunziata, Matthew H. Taylor, Erika Hamilton, Haeseong Park, Mary L. Disis, Jorge Chaves, James L. Gulley, Kathleen M. Moore, Alain C. Mita
Publikováno v:
JAMA oncology. 5(3)
Importance Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. Objective To assess the efficacy and safety of avelumab, an anti
Autor:
Melinda L. Telli, Roohi Ismail-Khan, Chiun-Sheng Huang, Sherko Kümmel, Rafael López, Ingrid A. Mayer, J. Thaddeus Beck, Paloma Martín-Martorell, Marina Parton, Shin-Cheh Chen, Aditya Bardia, Daniel Carreon, Laura G. Estévez, Serena Liao, Scott Cameron, Sara A. Hurvitz, Manuel Ruiz-Borrego, Javier Cortes, José Baselga, Sung-Bae Kim
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Purpose There are currently no targeted therapies approved for triple-negative breast cancer (TNBC). A tumor necrosis factor α ( TNFα)–based gene expression signature (GS) predictive of sensitivity to LCL161, inhibitor of apoptosis antagonist, wa
Autor:
Nelly Failloux, J. Thaddeus Beck, Robert Daly, Ruth Pettengell, Donald Quick, Kai Hübel, James P Dean, Shaker R. Dakhil, Mariya Pavlyuk, Lowell F Inhorn, David Belada, Pencho Georgiev, David Andorsky
Publikováno v:
Future Oncology. 12:1759-1768
We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or fol